AI assistant
scPharmaceuticals Inc. — Director's Dealing 2025
Oct 7, 2025
33303_dirs_2025-10-07_7c4a452e-46e1-4085-b61b-768e66050df2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: scPharmaceuticals Inc. (SCPH)
CIK: 0001604950
Period of Report: 2025-10-07
Reporting Person: Baylor-Henry Minnie (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-10-07 | Stock Option (Right to Buy) | $3.85 | D | 30000 | Disposed | 2035-06-03 | Common Stock (30000) | Direct |
| 2025-10-07 | Stock Option (Right to Buy) | $4.11 | D | 19750 | Disposed | 2034-06-11 | Common Stock (19750) | Direct |
| 2025-10-07 | Stock Option (Right to Buy) | $4.53 | D | 16300 | Disposed | 2032-06-14 | Common Stock (16300) | Direct |
| 2025-10-07 | Stock Option (Right to Buy) | $3.37 | D | 6124 | Disposed | 2029-06-18 | Common Stock (6124) | Direct |
| 2025-10-07 | Stock Option (Right to Buy) | $4.8 | D | 12248 | Disposed | 2028-07-20 | Common Stock (12248) | Direct |
Footnotes
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash,
F2: (Continued from footnote 1) without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.